Eagle Pharmaceuticals Inc Capital Reinvestment Ratio
Eagle Pharmaceuticals Inc capital reinvestment ratio. Eagle Pharmaceuticals Inc (EGRX) has a Capital Reinvestment Ratio of 0.00x as of December 2022, meaning it reinvests 0% of its operating cash flow ($37.56 Million) in capital expenditures ($10.00K). Check EGRX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Eagle Pharmaceuticals Inc (2016–2022)
Capital reinvestment ratio of Eagle Pharmaceuticals Inc from 2016 to 2022. This chart tracks Eagle Pharmaceuticals Inc's Capital Reinvestment Ratio across 7 annual periods. Also explore how fast is Eagle Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Eagle Pharmaceuticals Inc Capital Reinvestment Ratio by Year (2016–2022)
Eagle Pharmaceuticals Inc capital reinvestment ratio by year from 2016 to 2022. For the full cash flow conversion analysis, see Eagle Pharmaceuticals Inc (EGRX) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | $30.80 Million | $178.00K | ▼ -49.5% |
| 2021 | 0.01x | $28.22 Million | $323.00K | ▼ -24.2% |
| 2020 | 0.02x | $49.50 Million | $747.00K | ▲ +8.7% |
| 2019 | 0.01x | $55.99 Million | $777.00K | ▲ +446.6% |
| 2018 | 0.00x | $52.38 Million | $133.00K | ▼ -97.1% |
| 2017 | 0.09x | $58.92 Million | $5.19 Million | ▼ -77.4% |
| 2016 | 0.39x | $53.21 Million | $20.69 Million | — |